A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/orMycobacterium tuberculosis–infected Adults

Multifunctional, High-Level Cytokine-Producing Th1 Cells in the Lung, but Not Spleen, Correlate with Protection against Mycobacterium tuberculosis Aerosol Challenge in Mice

(2014) E. K. Forbes et al.   JOURNAL OF IMMUNOLOGY

Prospects for elimination of childhood tuberculosis: the role of new vaccines

(2011) M. Hatherill   ARCHIVES OF DISEASE IN CHILDHOOD

HIV-1/Mycobacterium tuberculosisCoinfection Immunology: How Does HIV-1 Exacerbate Tuberculosis?

(2011) Collin R. Diedrich et al.   INFECTION AND IMMUNITY

Functional Capacity of Mycobacterium tuberculosis-Specific T Cell Responses in Humans Is Associated with Mycobacterial Load

(2011) C. L. Day et al.   JOURNAL OF IMMUNOLOGY

Dose-Finding Study of the Novel Tuberculosis Vaccine, MVA85A, in Healthy BCG-Vaccinated Infants

(2011) Thomas J. Scriba et al.   JOURNAL OF INFECTIOUS DISEASES

A multistage tuberculosis vaccine that confers efficient protection before and after exposure

(2011) Claus Aagaard et al.   NATURE MEDICINE

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants

(2011) M. O. C. Ota et al.   Science Translational Medicine

Prevention of tuberculosis in Bacille Calmette–Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine

(2010) Charles F von Reyn et al.   AIDS

Specific T Cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis after Bacillus Calmette-Guérin Vaccination of Newborns

(2010) Benjamin M. N. Kagina et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Preferential infection and depletion ofMycobacterium tuberculosis–specific CD4 T cells after HIV-1 infection

(2010) Christof Geldmacher et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: A phase III study in Tanzania

(2010) Timothy Lahey et al.   VACCINE

Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa

(2009) Stephen D Lawn et al.   AIDS

Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, inMycobacterium tuberculosis–infected Individuals

(2009) Clare R. Sander et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

HIV-1 Infection Impairs the Bronchoalveolar T-Cell Response to Mycobacteria

(2009) Barbara Kalsdorf et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

(2009) Thomas J. Scriba et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Clinical Prognostic Value of RNA Viral Load and CD4 Cell Counts during Untreated HIV-1 Infection—A Quantitative Review

(2009) Eline L. Korenromp et al.   PLoS One

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A

(2009) Kathryn T. Whelan et al.   PLoS One

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

(2009) L. J. Abu-Raddad et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa

(2008) Tony Hawkridge et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa

(2008) Roger H. Brookes et al.   PLoS One

Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations

(2008) Willem A Hanekom et al.   PLOS MEDICINE

Eliminating human tuberculosis in the twenty-first century

(2007) C. Dye et al.   Journal of the Royal Society Interface